This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 3 for:    PCI brain breast cancer
Previous Study | Return to List | Next Study

PCI in Advanced Triple Negative Breast Cancer Patients Who Response to 1st Line Chemotherapy

This study is not yet open for participant recruitment.
See Contacts and Locations
Verified May 2017 by wang shusen, Sun Yat-sen University
Sponsor:
Information provided by (Responsible Party):
wang shusen, Sun Yat-sen University
ClinicalTrials.gov Identifier:
NCT02448576
First received: May 5, 2015
Last updated: May 30, 2017
Last verified: May 2017
  Purpose
The purpose of this study is to compare whether prophylactic cranial irradiation in patients with advanced triple negative breast cancer who had a response to first line chemotherapy could prolong brain-metastasis free survival.

Condition Intervention
Breast Cancer Brain Metastasis Radiation: prophylactic cranial irradiation

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Prevention
Official Title: A Phase III Randomized Controlled Trial of Prophylactic Cranial Irradiation in Patients With Advanced Triple Negative Breast Cancer Who Had a Response to First Line Chemotherapy

Resource links provided by NLM:


Further study details as provided by wang shusen, Sun Yat-sen University:

Primary Outcome Measures:
  • brain metastasis-free survival [ Time Frame: eight years ]
    time from randomization to brain metastasis


Secondary Outcome Measures:
  • cumulative risk of brain metastases within 1 year [ Time Frame: one year ]
    the percent of subjects occurring brain metastases with 1 year

  • progression-free survival [ Time Frame: eight years ]
    time from randomization to disease progression or death(upon which happen earlier)

  • overall survival [ Time Frame: eight years ]
    time from randomization to death

  • life quality score [ Time Frame: eight years ]
    quality of life measured by the EORTC-QLQ-C30 questionnaire score

  • central nervous function score [ Time Frame: eight years ]
    function of central nervous measured by the EORTC-QLQ-BN20 questionnaire score


Estimated Enrollment: 326
Anticipated Study Start Date: August 2017
Estimated Study Completion Date: August 2025
Estimated Primary Completion Date: August 2025 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PCI group
Receiving prophylactic cranial irradiation after response to first line chemotherapy.
Radiation: prophylactic cranial irradiation
Prophylactic cranial irradiation in patients with advanced triple negative breast cancer who had a response to first line chemotherapy
No Intervention: observation group
Patients in the observation group do not receive prophylactic cranial irradiation after response to first line chemotherapy.

Detailed Description:
This is a phase III, randomized, controlled, open, multicenter clinical trial, designed to assess the efficacy and safety of prophylactic cranial irradiation (PCI) in advanced triple negative breast cancer who response to the first line chemotherapy. Compare the PCI group with the observation group to evaluate brain metastasis-free survival,cumulative risk of brain metastases within 1 year,progression-free survival,overall survival,quality of life measured by the The Europe organization for research and treatment of cancer, Quality of life Questionnaire-cancer 30 (EORTC-QLQ-C30) questionnaire score and function of central nervous measured by the The Europe organization for research and treatment of cancer, Quality of life Questionnaire-brain cancer 20 (EORTC-QLQ-BN20) questionnaire score in women with advanced triple negative breast cancer who response to the first line chemotherapy.
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Signed informed consent;
  2. Age of 18 to 65 years;
  3. Documented advanced breast cancer, clinical and pathological confirmed;
  4. Immunohistochemical examination:ER<1%+, progestin receptor (PR)<1%+, HER-2 -/+ or HER-2(++)with negative result of FISH;
  5. A response after four to eight cycles of first line chemotherapy;
  6. Life expectancy longer than six months evaluated by investigator;
  7. A performance status of 0 to 2, according to the criteria of the World Health Organization (with a higher score indicating a poorer performance status)
  8. Less than grade 1( Common Terminology Criteria grade version 4.0) of treatment-related toxicities;
  9. Adequate baseline organ function.

Exclusion Criteria:

  1. History of another malignancy.
  2. Pregnancy or gestation
  3. Definite diagnosed of central nervous system (CNS)or leptomeningeal metastases
  4. Serious cardiac illness or medical condition
  5. Known history of related central nervous system or leptomeningeal disease
  6. Cognition impairment or suffering from mental illness
  7. Demand a long-term oral administration of psychotropic drugs
  8. Have a concurrent disease or condition that may interfere with study participation, or any serious medical disorder that would interfere with the subject's safety (for example, active or uncontrolled infection, currently active/requiring anti-viral therapy hepatic or biliary disease)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02448576

Contacts
Contact: fei Xu 862087342693 xufei@sysucc.org.cn

Locations
China, Guangdong
State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center Recruiting
Guangzhou, Guangdong, China, 510060
Contact: fei xu, M.D.    862087342693    xufei@sysucc.org.cn   
Sponsors and Collaborators
wang shusen
Investigators
Study Chair: Shusen Wang Sun Yat-sen University
  More Information

Publications:

Responsible Party: wang shusen, Shusen Wang, M.D. Department of Medical Oncology, Sun Yat-sen University Cancer Center, Sun Yat-sen University
ClinicalTrials.gov Identifier: NCT02448576     History of Changes
Other Study ID Numbers: SYSU-5010-TNBC-PCI
Study First Received: May 5, 2015
Last Updated: May 30, 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by wang shusen, Sun Yat-sen University:
phase 3 randomized controlled trial
prophylactic cranial irradiation
triple negative breast cancer
brain metastasis
advanced breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasm Metastasis
Triple Negative Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Neoplastic Processes
Pathologic Processes

ClinicalTrials.gov processed this record on July 26, 2017